NLRP3 and coronary artery disorder: Subsequently, in COLCOT (Colchicine Cardiovascular Outcomes Trial) and the LoDoCo2 (Low-dose Colchicine 2) trial, colchicine, an inhibitor of the NLRP3 inflammasome, was reported to be effective in the secondary prevention in patients with coronary artery disease (CAD) [4,5].